spot_imgspot_imgspot_imgspot_img
HomePress ReleaseEIN PresswireRapid Dose Therapeutics Corp. Corporate Update

Rapid Dose Therapeutics Corp. Corporate Update


Rapid Dose Therapeutics Corp. Corporate Update

Rapid Dose Therapeutics (CSE:DOSE)

BURLINGTON, ON, CANADA, July 7, 2023/EINPresswire.com/ — July 7, 2023 – Burlington, ON: Rapid Dose Therapeutics Corp. (“RDT” or the “Firm”) (CSE: DOSE) is happy to share an replace on its present progress in varied segments of its enterprise.

The Annual Basic and Particular Assembly of the shareholders of Rapid Dose Therapeutics Corp. (the “Firm”) might be held on August 1, 2023, at 295 The West Mall, sixth Ground, Toronto, Ontario M9C 4Z4 at [2:00 p.m.]

RDT’s flagship product QuickStrip™ is a skinny, orally dissolvable movie (sublingual strip) that may be infused with an infinite listing of lively elements which might be delivered into the bloodstream considerably enhancing the bioavailability and efficacy of such lively elements. The Firm views the “QuickStrip” expertise as a disruptive “platform” expertise answer which has the potential to revolutionize the standard “tablet, capsules, tablets and needles” supply mannequin. The “conventional” supply mannequin has many shortcomings that are addressed by the Firm’s sublingual strip expertise together with:

• Poor bioavailability and gradual onset of motion (1).

• Antagonistic results on the liver, pancreas, kidneys, and abdomen (2).

• Larger than 40% of adults and kids expertise issue swallowing drugs (3).

Moreover, the Firm has expanded its gross sales and advertising efforts from a “B2C” (business-to-consumer) mannequin to give attention to a “B2B” (business-to-business) channel companion enterprise mannequin. The focused channel companions have already got a powerful B2C market presence. The Firm’s QuickStrip™ expertise platform gives another supply technique having considerably larger bioavailability and efficacy. RDT’s goal market verticals embrace dental, nicotine, prescribed drugs (medicine and vaccines), varied nutraceutical options, and hashish. The specified outcomes give attention to managing a number of well being situations together with dry mouth, smoking dependancy, drug dependancy, reminiscence, erectile dysfunction, ache remedy plus quite a few normal wholesome dwelling options.

Within the dental section, the Firm is happy to announce the profitable launch of two preliminary dental merchandise, Xylitol and Lidocaine strips. The “Xylitol” answer addresses “dry mouth”, a critical well being situation affecting larger than 25% of the North American inhabitants (4). the Xerostomia (Dry Mouth) Therapeutics market in Canada is forecast to develop at 3.5% over the interval of 2022-2030 (5). “Lidocaine” is another ache remedy which manages ache and replaces different ache remedy options throughout dental procedures. These merchandise had been showcased on the Ontario Dental Affiliation and Journee’s dentaires internationales du Québec dental conventions in Toronto and Montreal final month, the place dental professionals skilled their advantages firsthand. Xylitol and Lidocaine strips at the moment are accessible to dental places of work and pharmacies nationwide by means of RDT’s trusted distributors, Henry Schein and Skycare.

Within the nicotine section, the Firm has entered right into a analysis and improvement (“R&D”) undertaking in collaboration with one of many world’s largest tobacco producers. The target is to develop a brand new nicotine product, full with flavoring and packaging. The Firm anticipates submitting an FDA approval software for the US market by the autumn of 2023. Moreover, the Firm’s tobacco collaborator has engaged a third-party advertising agency to create a complete international forecast. Moreover, a human nicotine trial involving 24 sufferers is being performed to judge its impression on coronary heart well being compared to different nicotine merchandise. RDT’s focus might be manufacturing and “R&D”. The nicotine market is critical as presently there are over 20 billion cigarettes being consumed each day on a world foundation (6), and the Firm’s channel companion is among the business’s largest gamers.

Within the pharmaceutical section, the Firm is within the means of launching Tadalafil and Sildenafil (generic variations of Cialis and Viagra), each confirmed erectile dysfunction molecules. These merchandise might be accessible to medical doctors, pharmacies, and hospitals. The chance in addressing erectile disfunction is a big market alternative. It impacts roughly 40% of males by age 40 and almost 70% by age 70 (7). In 2021, the worldwide market was estimated to be roughly US$2.296 billion rising at over 8% every year (7). RDT is dedicated to creating a considerable impression on this area.

Within the vaccine section, the Firm has initiated a analysis undertaking with a big pharmaceutical firm to combine their vaccines into RDT’s strips. Moreover, the Firm is collaborating with a US-based vaccine supplier to load their Plasma DNA vaccines onto RDT’s strips. Moreover, the Firm is partnering with a US-based college to analysis the flexibility to infuse a Fentanyl vaccine into the QuickStrip. This specific vaccine is a novel providing which addresses the rising opioid dependancy disaster in North America by curbing the drug craving. Some great benefits of sublingual strip expertise within the vaccine market are probably in depth and embrace:

• Eliminating the necessity for needles.

• Eliminating the necessity for chilly chain or reconstitution.

• Eliminating the necessity for certified well being care skilled administration.

• Exact and reproducible dosing.

• Value financial savings at authorities and native ranges.

The Firm’s nutraceutical merchandise are presently accessible in over 378 “Circle Okay” areas, and grocery retailers with greater than 500 areas, together with a number of impartial shops and “Relay” shops at airports in addition to by means of on-line e-commerce channels. This distribution community ensures that buyers have handy entry to the Firm’s nutraceutical merchandise throughout varied retail channels. RDT has greater than 40 nutraceutical formularies accessible on its sublingual strips.

Within the hashish section, the Firm has established sturdy collaborations with famend organizations corresponding to Tilray, Thrive-Aurora, Phoena, and Eco Organics for the Firm’s white label merchandise. These merchandise at the moment are accessible in most government-operated hashish shops throughout Canada. The Firm’s crew is presently growing a complete well being & wellness package deal and actively engaged on personal model label initiatives, with new formulation. RDT has additionally initiated channel companion negotiations for entry into the US market.

A brand new director, John McKimm, has just lately joined the Firm’s board of administrators. Mr. McKimm has a historical past of success with rising firms and in depth international and public firm transaction and operational experience, together with launching channel companion “B2B” and “B to B to C” enterprise fashions. The Firm anticipates further new administrators might be elected on the Firm’s subsequent shareholders’ assembly; all of whom are anticipated to convey broad experience and strategic worth to the Firm.

RDT just lately introduced a $5.0M convertible notice financing which is predicted to completely shut by July 31, 2023. With the profitable completion of such financing, it’s anticipated that the $5.0M of convertible notes would be the solely debt within the Firm and can strengthen the RDT stability sheet and money place and provides the Firm the runway to attain optimistic money circulate. The Firm believes that after a few years of analysis and improvement, with over 40 confirmed formularies, RDT is now at an inflection level in expediting a extremely worthwhile enterprise mannequin.

States Mark Upsell, CEO of RDT: “RDT has made substantial progress since its inception in 2018. We now have confirmed the efficacy and advantages of the “sublingual strip” supply platform for a number of pharmaceutical and nutraceutical lively elements together with elements to handle situations corresponding to dry mouth, smoking dependancy, drug dependancy, reminiscence, erectile dysfunction and ache remedy. The introduced financing is over 50% dedicated, the bulk by present buyers and new administrators. The addition of recent administrators is predicted to considerably will increase our enterprise experience and opens new market alternatives. We now have over 40 confirmed formularies, many representing RDT mental property. Moreover, RDT has confirmed manufacturing experience throughout many varieties of lively elements and environmental situations. That is thought-about a considerable aggressive benefit. The manufacturing course of and the mix of distinctive lively elements with the sublingual strip additionally lends itself to a number of “patent” alternatives. We imagine RDT is at an inflection level the place all of the laborious work and dedication of administration, workers and strategic companions since inception will come collectively to expedite long run sustainable development alternatives.”

About Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics is a Canadian biotechnology firm revolutionizing drug supply by means of innovation. The Firm’s flagship product QuickStrip™ is a skinny, orally dissolvable movie, that may be infused with an infinite listing of lively elements, together with nutraceuticals, prescribed drugs and vaccines, which might be delivered shortly into the bloodstream, leading to fast onset of the lively ingredient. For extra details about the Firm, go to www.rapid-dose.com.

Contacts:

RDT Investor Contact:

Mark Upsdell, CEO

mupsdell@rapid-dose.com

416-477-1052

References

1. Hines RM., Khumnark M, Macphail B and Hines DJ. (2019) Administration of Micronized Caffeine Utilizing a Novel Oral Supply Movie Ends in Rapid Absorption and Electroencephalogram Suppression. Entrance. Pharmacol. 10:983. doi: 10.3389/fphar.2019.00983

2. Medsafe. (2017). Pancreatitis and drug-induced pancreatitis.

3. DeRoche, C., Macclaren, G., & Sonies, B. (2000). Capsule swallowing in America: A nationwide survey of adults. In Poster, Dysphagia Analysis Society Annual Assembly, Savannah GA.

4. 4. Nederfors, T. (1996). Xerostomia: prevalence and pharmacotherapy. With particular reference to beta-adrenoceptor antagonists. Swedish Dental Journal, 116, 1-70.

5. MarketResearch.com. (2022). Xerostomia (Dry Mouth) Therapeutics – World Market Trajectory & Analytics.

6. Verified Market Analysis. (2021). Smokeless Tobacco Market by sort (Chewing tobacco, Dipping tobacco, Dry snuff, Moist Snuff), by Distribution Channel (Offline, On-line). Retrieved July 06, 2023, from https://www.verifiedmarketresearch.com/product/smokeless-tobacco-market/

7. Skyquest Know-how Consulting Non-public Restricted. (2021). Erectile Dysfunction Market – World Trade Evaluation, Dimension, Share, Progress, Tendencies, and Forecast, 2021-2031. Retrieved July 06, 2023, from https://www.skyquestt.com/report/erectile-dysfunction-market

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

Sure info on this information launch could comprise forward-looking info inside the which means of relevant securities legal guidelines. Any statements which might be contained on this information launch that aren’t statements of historic reality could also be deemed to be forward-looking statements. Ahead-looking statements are sometimes recognized by phrases corresponding to “could”, “ought to”, “anticipate”, “anticipate”, “potential”, “imagine”, “intend”, “will”, “might”, “are deliberate to”, “are anticipated to” or the destructive of those phrases and comparable expressions. Statements containing forward-looking info, together with, with out limitation, in respect of the supply of apparatus and merchandise utilizing the QuickStrip™ product supply technique, the era of recurring revenues, the plans, estimates, forecasts, projections, expectations or beliefs of RDT administration as to future occasions or outcomes and are believed to be cheap primarily based on info presently accessible to RDT administration. Ahead-looking statements essentially contain recognized and unknown dangers, together with, with out limitation, dangers related to normal financial situations; opposed business occasions; advertising prices; lack of markets; termination of WLM agreements; future legislative and regulatory developments involving hashish; incapacity to entry adequate capital from inner and exterior sources, and/or incapacity to entry adequate capital on beneficial phrases; the hashish business in Canada usually, earnings tax and regulatory issues; the flexibility to implement its enterprise methods; competitors; forex and rate of interest fluctuations and different dangers. Readers are cautioned that the foregoing listing shouldn’t be exhaustive. There might be no assurance that statements of forward-looking info, though thought-about cheap by RDT administration on the time of preparation, will show to be correct as there might be no assurance that the plans, intentions or expectations upon which they’re primarily based will happen. Precise outcomes and future occasions might differ materially from these anticipated in such forward-looking statements. Readers mustn’t place undue reliance on forward-looking statements. Ahead-looking statements contained on this information launch are expressly certified by this cautionary assertion. The forward-looking statements contained on this information launch are made as of the date of this information launch, and the Firm expressly disclaims any obligation to replace or alter statements containing any forward-looking info, or the elements or assumptions underlying them, whether or not because of new info, future occasions or in any other case, besides as required by regulation.

This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase nor shall there be any sale of the securities in any jurisdiction by which such provide, solicitation or sale can be illegal. This press launch doesn’t represent a suggestion to promote or a solicitation of a suggestion to promote any of the securities described herein in america. The securities described on this information launch haven’t been and won’t be registered below america Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities legal guidelines and is probably not supplied or bought inside america or to U.S. Individuals until registered below the U.S. Securities Act and relevant state securities legal guidelines or an exemption from such registration is accessible.

Mark Upsdell
Rapid Dose Therapeutics
+1 4164771052
mupsdell@rapid-dose.com
Go to us on social media:
Twitter
LinkedIn
Instagram
YouTube



RELATED ARTICLES

Most Popular